Spark Therapeutics is leveraging our unique technical and R&D expertise as we strive to bring gene therapies to patients. One of our areas of research includes hemophilia A, an inherited bleeding disorder caused by mutations in the gene that encodes clotting factor VIII. Led by researchers and clinicians with long-standing commitment to the hemophilia community, we recognize the essential need to understand and gain important perspectives from patients, caregivers and leaders in the community.